Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods

被引:22
作者
Cao, W
Matherly, LH
机构
[1] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA
关键词
folate; 3-(N-maleimidylpropionyl)-biocytin; membrane topology; methotrexate; transmembrane domain; transporter;
D O I
10.1042/BJ20031288
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hRFC (human reduced folate carrier) is the major membrane transporter for both reduced folates and antifolates in human tissues and tumours. The primary amino acid sequence of hRFC predicts a membrane topology involving 12 TMDs (transmembrane domains) with cytosolic oriented N- and C-termini, and a large internal loop connecting TMDs 6 and 7. Previous studies using haemagglutinin epitope insertion and scanning glycosylation mutagenesis methods verified portions of the predicted topology model, including TMDs 1-8 and the N- and C-termini of hRFC. However, the topology structure for TMDs 9-12 remains controversial. To further determine the membrane topology of the hRFC protein, single cysteine residues were introduced into the predicted extracellular or cytoplasmic loops of a fully functional cysteine-less hRFC expressed in transport impaired MtxRIIOua(R)2-4 Chinese hamster ovary cells. The membrane orientations of the substituted cysteines were determined by treatments with the thiol reagents 3-(N-maleimidylpropionyl)-biocytin (biotin maleimide) and 4-acetamido-4'maleimidylstilbene-2,2'-disulphonic acid (stil-benedisulphonate maleimide; SM) or N-ethylmaleimide, combined with the cell-permeabilizing reagent SLO (streptolysin 0). We found that cysteine residues placed in the predicted extracellular loops between TMDs 7 and 8 (position 301), 9 and 10 (360), and 11 and 12 (429) could be biotinylated with 200 muM biotin maleimide, and labelling could be blocked with SM. However, biotinylation of cysteines placed in the predicted intracellular loops between TMDs 8 and 9 (position 332) and TMDs 10 and 11 (position 388) was only detected after cell permeabilization with SLO and was abolished by pre-treatment with N-ethylmaleimide. These results strongly support a 12-TMD topology structure for the hRFC protein.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 36 条
[1]  
BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167
[2]   Characterization of a cysteine-less human reduced folate carrier: localization of a substrate-binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods [J].
Cao, W ;
Matherly, LH .
BIOCHEMICAL JOURNAL, 2003, 374 (01) :27-36
[3]  
CLARKE AR, 1998, COMPREHENSIVE BIOL C, V3, P1
[4]   Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion [J].
Ferguson, PL ;
Flintoff, WF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (23) :16269-16278
[5]   The region between transmembrane domains 1 and 2 of the reduced folate carrier forms part of the substrate-binding pocket [J].
Flintoff, WF ;
Williams, FMR ;
Sadlish, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :40867-40876
[6]   ISOLATION AND PARTIAL CHARACTERIZATION OF 3 METHOTREXATE-RESISTANT PHENOTYPES FROM CHINESE-HAMSTER OVARY CELLS [J].
FLINTOFF, WF ;
DAVIDSON, SV ;
SIMINOVITCH, L .
SOMATIC CELL GENETICS, 1976, 2 (03) :245-261
[7]  
FRY DW, 1982, J BIOL CHEM, V257, P1890
[8]   THE CELLULAR PHARMACOLOGY OF METHOTREXATE [J].
GOLDMAN, ID ;
MATHERLY, LH .
PHARMACOLOGY & THERAPEUTICS, 1985, 28 (01) :77-102
[9]   Molecular, biochemical, and cellular pharmacology of pemetrexed [J].
Goldman, ID ;
Zhao, RB .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :3-17
[10]   Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line [J].
Gong, MK ;
Yess, J ;
Connolly, T ;
Ivy, SP ;
Ohnuma, T ;
Cowan, KH ;
Moscow, JA .
BLOOD, 1997, 89 (07) :2494-2499